Ahmed A, et al. - Authors conducted a retrospective observational study to describe the safety and effectiveness of treating scleritis and uveitis with either cyclophosphamide or rituximab in granulomatosis with polyangiitis (GPA). Throughout the course of treatment, no adverse side effects of rituximab were noted. Findings suggested that for controlling scleritis and uveitis associated with GPA, with eventual progression towards steroid-sparing remission, cyclophosphamide and rituximab were safe and effective agents.